Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 2/2020

01-04-2020 | Metastasis | Review

Toll-like receptors: exploring their potential connection with post-operative infectious complications and cancer recurrence

Authors: S. D. Gowing, J. J. Cool-Lartigue, J. D. Spicer, A. J. E. Seely, L. E. Ferri

Published in: Clinical & Experimental Metastasis | Issue 2/2020

Login to get access

Abstract

Cancer is the leading cause of death in North America. Despite modern advances in cancer therapy, many patients will ultimately develop cancer metastasis resulting in mortality. Surgery to resect early stage solid malignancies remains the cornerstone of cancer treatment. However, surgery places patients at risk of developing post-operative infectious complications that are linked to earlier cancer metastatic recurrence and cancer mortality. Toll-like receptors (TLRs) are evolutionarily-conserved sentinel receptors of the innate immune system that are activated by microbial products present during infection, leading to activation of innate immunity. Numerous types of solid cancer cells also express TLRs, with their activation augmenting their ability to metastasize. Similarly, healthy host-tissue TLRs activated during infection induce a prometastatic environment in the host. Cancer cells additionally secrete TLR activating ligands that activate both cancer TLRs and host TLRs to promote metastasis. Consequently, TLRs are an attractive therapeutic candidate to target infection-induced cancer metastasis and progression.
Literature
1.
Miller KD, Siegel RL, Lin CC et al (2016) Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66:271–289PubMedCrossRef
2.
Statistics CCSsACoC (2017) Canadian cancer statistics 2017. Canadian Cancer Society, Ontario
3.
4.
Nguyen DX, Bos PD, Massague J (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9:274–284PubMedCrossRef
5.
Takeuchi H, Saikawa Y, Oyama T et al (2010) Factors influencing the long-term survival in patients with esophageal cancer who underwent esophagectomy after chemoradiotherapy. World J Surg 34:277–284PubMedCrossRef
6.
Andreou A, Aloia TA, Brouquet A et al (2013) Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg 257:1079PubMedCrossRef
7.
Matull WR, Dhar DK, Ayaru L et al (2011) R0 but not R1/R2 resection is associated with better survival than palliative photodynamic therapy in biliary tract cancer. Liver Int 31:99–107PubMedCrossRef
8.
Khan O, Goh S, Byrne B et al (2011) Long-term outcomes of extended proximal gastrectomy for oesophagogastric junctional tumours. World J Surg 35:2245–2251PubMedCrossRef
9.
10.
Uramoto H, Tanaka F (2012) Prediction of recurrence after complete resection in patients with NSCLC. Anticancer Res 32:3953–3960PubMed
11.
Sawabata N, Okumura M, Utsumi T et al (2007) Circulating tumor cells in peripheral blood caused by surgical manipulation of non-small-cell lung cancer: pilot study using an immunocytology method. Gen Thorac Cardiovasc Surg 55:189–192PubMedCrossRef
12.
Pesta M, Fichtl J, Kulda V et al (2013) Monitoring of circulating tumor cells in patients undergoing surgery for hepatic metastases from colorectal cancer. Anticancer Res 33:2239–2243PubMed
13.
Papavasiliou P, Fisher T, Kuhn J et al (2010) Circulating tumor cells in patients undergoing surgery for hepatic metastases from colorectal cancer. Proc (Bayl Univ Med Cent) 23:11–14CrossRef
14.
Fidler IJ (1970) Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2′-deoxyuridine. J Natl Cancer Inst 45:773–782PubMed
15.
Tsubura E, Yamashita T, Sone S (1983) Inhibition of the arrest of hematogenously disseminated tumor cells. Cancer Metastasis Rev 2:223–237PubMedCrossRef
16.
17.
Groot Koerkamp B, Rahbari NN, Buchler MW et al (2013) Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Ann Surg Oncol 20:2156–2165PubMedCrossRef
18.
Neki K, Kawahara H, Watanabe K et al (2013) Usefulness of circulating tumor cells after preliminary chemotherapy for prediction of response to further anticancer therapy in patients with initially unresectable metastatic colorectal cancer. Anticancer Res 33:1769–1772PubMed
19.
Rahbari NN, Reissfelder C, Muhlbayer M et al (2011) Correlation of circulating angiogenic factors with circulating tumor cells and disease recurrence in patients undergoing curative resection for colorectal liver metastases. Ann Surg Oncol 18:2182–2191PubMedCrossRef
20.
Nespoli A, Gianotti L, Bovo G et al (2006) Impact of postoperative infections on survival in colon cancer patients. Surg Infect (Larchmt) 7(Suppl 2):S41–43CrossRef
21.
Radu DM, Jaureguy F, Seguin A et al (2007) Postoperative pneumonia after major pulmonary resections: an unsolved problem in thoracic surgery. Ann Thorac Surg 84:1669–1673PubMedCrossRef
22.
Schussler O, Alifano M, Dermine H et al (2006) Postoperative pneumonia after major lung resection. Am J Respir Crit Care Med 173:1161–1169PubMedCrossRef
23.
Pisters PW, Hudec WA, Hess KR et al (2001) Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients. Ann Surg 234:47–55PubMedPubMedCentralCrossRef
24.
Matsuo K, Prather CP, Ahn EH et al (2012) Significance of perioperative infection in survival of patients with ovarian cancer. Int J Gynecol Cancer 22:245–253PubMedCrossRef
25.
Andalib A, Ramana-Kumar AV, Bartlett G et al (2013) Influence of postoperative infectious complications on long-term survival of lung cancer patients: a population-based cohort study. J Thorac Oncol 8:554–561PubMedCrossRef
26.
Kinugasa S, Tachibana M, Yoshimura H et al (2004) Postoperative pulmonary complications are associated with worse short- and long-term outcomes after extended esophagectomy. J Surg Oncol 88:71–77PubMedCrossRef
27.
Tsujimoto H, Ichikura T, Ono S et al (2009) Impact of postoperative infection on long-term survival after potentially curative resection for gastric cancer. Ann Surg Oncol 16:311–318PubMedCrossRef
28.
Tokunaga M, Tanizawa Y, Bando E et al (2013) Poor survival rate in patients with postoperative intra-abdominal infectious complications following curative gastrectomy for gastric cancer. Ann Surg Oncol 20:1575–1583PubMedCrossRef
29.
Tan HJ, Hafez KS, Ye Z et al (2012) Postoperative complications and long-term survival among patients treated surgically for renal cell carcinoma. J Urol 187:60–66PubMedCrossRef
30.
Walker KG, Bell SW, Rickard MJ et al (2004) Anastomotic leakage is predictive of diminished survival after potentially curative resection for colorectal cancer. Ann Surg 240:255–259PubMedPubMedCentralCrossRef
31.
Nespoli A, Gianotti L, Totis M et al (2004) Correlation between postoperative infections and long-term survival after colorectal resection for cancer. Tumori 90:485–490PubMedCrossRef
32.
den Dulk M, Marijnen CA, Collette L et al (2009) Multicentre analysis of oncological and survival outcomes following anastomotic leakage after rectal cancer surgery. Br J Surg 96:1066–1075CrossRef
33.
Lin JK, Yueh TC, Chang SC et al (2011) The influence of fecal diversion and anastomotic leakage on survival after resection of rectal cancer. J Gastrointest Surg 15:2251–2261PubMedCrossRef
34.
Indelicato D, Grobmyer SR, Newlin H et al (2007) Association between operative closure type and acute infection, local recurrence, and disease surveillance in patients undergoing breast conserving therapy for early-stage breast cancer. Surgery 141:645–653PubMedCrossRef
35.
36.
Rueth NM, Parsons HM, Habermann EB et al (2011) The long-term impact of surgical complications after resection of stage I nonsmall cell lung cancer: a population-based survival analysis. Ann Surg 254:368–374PubMedCrossRef
37.
Lerut T, Moons J, Coosemans W et al (2009) Postoperative complications after transthoracic esophagectomy for cancer of the esophagus and gastroesophageal junction are correlated with early cancer recurrence: role of systematic grading of complications using the modified Clavien classification. Ann Surg 250:798–807PubMedCrossRef
38.
Hayashi T, Yoshikawa T, Aoyama T et al (2015) Impact of infectious complications on gastric cancer recurrence. Gastric Cancer 18:368–374PubMedCrossRef
39.
Ohtsuka T, Kitajima Y, Takahashi T et al (2009) Infectious complications after gastric cancer surgery accelerate a rapid hepatic recurrence. Hepatogastroenterology 56:1277–1280PubMed
40.
Tsujimoto H, Ueno H, Hashiguchi Y et al (2010) Postoperative infections are associated with adverse outcome after resection with curative intent for colorectal cancer. Oncol Lett 1:119–125PubMedPubMedCentralCrossRef
41.
Jackson RM, Rice DH (1990) Wound infections and recurrence in head and neck cancer. Otolaryngol Head Neck Surg 102:331–333PubMedCrossRef
42.
Farid SG, Aldouri A, Morris-Stiff G et al (2010) Correlation between postoperative infective complications and long-term outcomes after hepatic resection for colorectal liver metastasis. Ann Surg 251:91–100PubMedCrossRef
43.
Haruki K, Shiba H, Fujiwara Y et al (2013) Negative impact of surgical site infection on long-term outcomes after hepatic resection for colorectal liver metastases. Anticancer Res 33:1697–1703PubMed
44.
Neal CP, Mann CD, Garcea G et al (2011) Preoperative systemic inflammation and infectious complications after resection of colorectal liver metastases. Arch Surg 146:471–478PubMedCrossRef
45.
Mirnezami A, Mirnezami R, Chandrakumaran K et al (2011) Increased local recurrence and reduced survival from colorectal cancer following anastomotic leak: systematic review and meta-analysis. Ann Surg 253:890–899PubMedCrossRef
46.
Pucher PH, Aggarwal R, Qurashi M, Darzi A (2014) Meta-analysis of the effect of postoperative in-hospital morbidity on long-term patient survival. Br J Surg 101:1499–1508PubMedCrossRef
47.
Kawai T, Akira S (2011) Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34:637–650PubMedCrossRef
48.
49.
Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11:373–384PubMedCrossRef
50.
Jiang D, Liang J, Fan J et al (2005) Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 11:1173–1179PubMedCrossRef
51.
Lucas M, Stuart LM, Savill J, Lacy-Hulbert A (2003) Apoptotic cells and innate immune stimuli combine to regulate macrophage cytokine secretion. J Immunol 171:2610–2615PubMedCrossRef
52.
Sabroe I, Prince LR, Jones EC et al (2003) Selective roles for Toll-like receptor (TLR)2 and TLR4 in the regulation of neutrophil activation and life span. J Immunol 170:5268–5275PubMedCrossRef
53.
Fan J, Malik AB (2003) Toll-like receptor-4 (TLR4) signaling augments chemokine-induced neutrophil migration by modulating cell surface expression of chemokine receptors. Nat Med 9:315–321PubMedCrossRef
54.
McDonald B, Spicer J, Giannais B et al (2009) Systemic inflammation increases cancer cell adhesion to hepatic sinusoids by neutrophil mediated mechanisms. Int J Cancer 125:1298–1305PubMedCrossRef
55.
Clark SR, Ma AC, Tavener SA et al (2007) Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 13:463–469PubMedCrossRef
56.
Schnare M, Barton GM, Holt AC et al (2001) Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2:947–950PubMedCrossRef
57.
58.
59.
Okamura Y, Watari M, Jerud ES et al (2001) The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 276:10229–10233CrossRefPubMed
60.
Schaefer L, Babelova A, Kiss E et al (2005) The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 115:2223–2233PubMedPubMedCentralCrossRef
61.
Guillot L, Balloy V, McCormack FX et al (2002) Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J Immunol 168:5989–5992PubMedCrossRef
62.
63.
Yanai H, Ban T, Wang Z et al (2009) HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 462:99–103PubMedCrossRef
64.
Hiratsuka S, Watanabe A, Sakurai Y et al (2008) The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol 10:1349–1355PubMedCrossRef
65.
Imai Y, Kuba K, Neely GG et al (2008) Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133:235–249PubMedPubMedCentralCrossRef
66.
Biragyn A, Ruffini PA, Leifer CA et al (2002) Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 298:1025–1029PubMedCrossRef
67.
D'Arpa P, Leung KP (2017) Toll-like receptor signaling in burn wound healing and scarring. Adv Wound Care (New Rochelle) 6:330–343CrossRef
68.
Braza F, Brouard S, Chadban S, Goldstein DR (2016) Role of TLRs and DAMPs in allograft inflammation and transplant outcomes. Nat Rev Nephrol 12:281–290PubMedCrossRefPubMedCentral
69.
Macedo L, Pinhal-Enfield G, Alshits V et al (2007) Wound healing is impaired in MyD88-deficient mice: a role for MyD88 in the regulation of wound healing by adenosine A2A receptors. Am J Pathol 171:1774–1788PubMedPubMedCentralCrossRef
70.
71.
Prince LR, Whyte MK, Sabroe I, Parker LC (2011) The role of TLRs in neutrophil activation. Curr Opin Pharmacol 11:397–403PubMedCrossRef
72.
Greene CM, McElvaney NG (2005) Toll-like receptor expression and function in airway epithelial cells. Archivum Immunologiae et Therapiae Experimentalis 53:418–427PubMed
73.
Hauber HP, Tulic MK, Tsicopoulos A et al (2005) Toll-like receptors 4 and 2 expression in the bronchial mucosa of patients with cystic fibrosis. Can Respir J 12:13–18PubMedCrossRef
74.
Zhang Z, Louboutin JP, Weiner DJ et al (2005) Human airway epithelial cells sense Pseudomonas aeruginosa infection via recognition of flagellin by Toll-like receptor 5. Infect Immun 73:7151–7160PubMedPubMedCentralCrossRef
75.
Kawai T, Akira S (2008) Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci 1143:1–20PubMedCrossRef
76.
Ishida I, Kubo H, Suzuki S et al (2002) Hypoxia diminishes toll-like receptor 4 expression through reactive oxygen species generated by mitochondria in endothelial cells. J Immunol 169:2069–2075PubMedCrossRef
77.
Fan J, Kapus A, Marsden PA et al (2002) Regulation of toll-like receptor 4 expression in the lung following hemorrhagic shock and lipopolysaccharide. J Immunol 168:5252–5259PubMedCrossRef
78.
Hopkins PA, Fraser JD, Pridmore AC et al (2005) Superantigen recognition by HLA class II on monocytes up-regulates toll-like receptor 4 and enhances proinflammatory responses to endotoxin. Blood 105:3655–3662PubMedCrossRef
79.
Nilsen N, Nonstad U, Khan N et al (2004) Lipopolysaccharide and double-stranded RNA up-regulate Toll-like receptor 2 independently of myeloid differentiation factor 88. J Biol Chem 279:39727–39735PubMedCrossRef
80.
Medzhitov R, Preston-Hurlburt P, Janeway CA Jr (1997) A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388:394–397PubMedCrossRef
81.
Kagan JC, Medzhitov R (2006) Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell 125:943–955PubMedCrossRef
82.
83.
Basith S, Manavalan B, Yoo TH et al (2012) Roles of toll-like receptors in cancer: a double-edged sword for defense and offense. Arch Pharm Res 35:1297–1316PubMedCrossRef
84.
Malley R, Henneke P, Morse SC et al (2003) Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci USA 100:1966–1971PubMedCrossRefPubMedCentral
85.
Park BS, Song DH, Kim HM et al (2009) The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458:1191–1195PubMedCrossRef
86.
Hayashi F, Smith KD, Ozinsky A et al (2001) The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410:1099–1103PubMedCrossRef
87.
Miao EA, Andersen-Nissen E, Warren SE, Aderem A (2007) TLR5 and Ipaf: dual sensors of bacterial flagellin in the innate immune system. Semin Immunopathol 29:275–288PubMedCrossRef
88.
Uematsu S, Jang MH, Chevrier N et al (2006) Detection of pathogenic intestinal bacteria by Toll-like receptor 5 on intestinal CD11c+ lamina propria cells. Nat Immunol 7:868–874PubMedCrossRef
89.
Uematsu S, Akira S (2009) Immune responses of TLR5(+) lamina propria dendritic cells in enterobacterial infection. J Gastroenterol 44:803–811PubMedCrossRef
90.
Uematsu S, Fujimoto K, Jang MH et al (2008) Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nat Immunol 9:769–776PubMedCrossRef
91.
92.
Bell JK, Botos I, Hall PR et al (2005) The molecular structure of the Toll-like receptor 3 ligand-binding domain. Proc Natl Acad Sci USA 102:10976–10980PubMedCrossRefPubMedCentral
93.
Cho WG, Albuquerque RJ, Kleinman ME et al (2009) Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. Proc Natl Acad Sci USA 106:7137–7142PubMedCrossRefPubMedCentral
94.
Harrison LI, Astry C, Kumar S, Yunis C (2007) Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans. J Clin Pharmacol 47:962–969PubMedCrossRef
95.
96.
97.
Gantier MP, Irving AT, Kaparakis-Liaskos M et al (2010) Genetic modulation of TLR8 response following bacterial phagocytosis. Hum Mutat 31:1069–1079PubMedCrossRef
98.
Mancuso G, Gambuzza M, Midiri A et al (2009) Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells. Nat Immunol 10:587–594PubMedCrossRef
99.
Coban C, Igari Y, Yagi M et al (2010) Immunogenicity of whole-parasite vaccines against Plasmodium falciparum involves malarial hemozoin and host TLR9. Cell Host Microbe 7:50–61PubMedCrossRef
100.
Lee SM, Yip TF, Yan S et al (2018) Recognition of double-stranded RNA and regulation of interferon pathway by Toll-like receptor 10. Front Immunol 9:516PubMedPubMedCentralCrossRef
101.
Hasan U, Chaffois C, Gaillard C et al (2005) Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol 174:2942–2950PubMedCrossRef
102.
Paget S (1989) The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev 8:98–101PubMed
103.
Sleeman JP, Thiele W (2009) Tumor metastasis and the lymphatic vasculature. Int J Cancer 125:2747–2756PubMedCrossRef
104.
Ran S, Volk L, Hall K, Flister MJ (2010) Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology 17:229–251PubMedCrossRef
105.
Luddy KA, Robertson-Tessi M, Tafreshi NK et al (2014) The role of toll-like receptors in colorectal cancer progression: evidence for epithelial to leucocytic transition. Front Immunol 5:429PubMedPubMedCentralCrossRef
106.
Spicer JD, Brodt P, Ferri LE (2011) The role of inflammation in the early stages of liver metastasis. In: Brodt P (ed) Liver metastasis: biology and clinical management. Springer Science and Business Media, Berlin, pp 155–185CrossRef
107.
Pearson HB, Pouliot N (2013) Modeling metastasis in vivo. In Jandial R (ed) Metastatic cancer: clinical and biological perspectives. Landes Bioscience, Melbourne
108.
Sutherland RM (1988) Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 240:177–184PubMedCrossRef
109.
110.
111.
112.
113.
Maroldi R, Farina D, Borghesi A et al (2008) Perineural tumor spread. Neuroimaging Clin N Am 18:413–429PubMedCrossRef
114.
Dajon M, Iribarren K, Cremer I (2017) Toll-like receptor stimulation in cancer: a pro- and anti-tumor double-edged sword. Immunobiology 222:89–100PubMedCrossRef
115.
Huang B, Zhao J, Shen S et al (2007) Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res 67:4346–4352PubMedCrossRef
116.
Kundu SD, Lee C, Billips BK et al (2008) The toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cells. Prostate 68:223–229PubMedCrossRef
117.
Grimmig T, Matthes N, Hoeland K et al (2015) TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer. Int J Oncol 47:857–866PubMedPubMedCentralCrossRef
118.
Cherfils-Vicini J, Platonova S, Gillard M et al (2010) Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest 120:1285–1297PubMedPubMedCentralCrossRef
119.
Luo JL, Maeda S, Hsu LC et al (2004) Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6:297–305PubMedCrossRef
120.
Hsu RY, Chan CH, Spicer JD et al (2011) LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrin-mediated cell adhesion and liver metastasis. Cancer Res 71:1989–1998PubMedCrossRef
121.
122.
Li D, Jin Y, Sun Y et al (2014) Knockdown of Toll-like receptor 4 inhibits human NSCLC cancer cell growth and inflammatory cytokine secretion in vitro and in vivo. Int J Oncol 45:813–821PubMedCrossRef
123.
Jing YY, Han ZP, Sun K et al (2012) Toll-like receptor 4 signaling promotes epithelial–mesenchymal transition in human hepatocellular carcinoma induced by lipopolysaccharide. BMC Med 10:98PubMedPubMedCentralCrossRef
124.
Wang CH, Wang PJ, Hsieh YC et al (2018) Resistin facilitates breast cancer progression via TLR4-mediated induction of mesenchymal phenotypes and stemness properties. Oncogene 37:589–600PubMedCrossRef
125.
Park GB, Kim D (2017) TLR4-mediated galectin-1 production triggers epithelial-mesenchymal transition in colon cancer cells through ADAM10- and ADAM17-associated lactate production. Mol Cell Biochem 425:191–202PubMedCrossRef
126.
Duan H, Qu L, Shou C (2014) Mycoplasma hyorhinis induces epithelial–mesenchymal transition in gastric cancer cell MGC803 via TLR4-NF-kappaB signaling. Cancer Lett 354:447–454PubMedCrossRef
127.
He Z, Deng R, Huang X et al (2015) Lipopolysaccharide enhances OSCC migration by promoting epithelial–mesenchymal transition. J Oral Pathol Med 44:685–692PubMedCrossRef
128.
Park GB, Kim D (2017) TLR5/7-mediated PI3K activation triggers epithelial-mesenchymal transition of ovarian cancer cells through WAVE3-dependent mesothelin or OCT4/SOX2 expression. Oncol Rep 38:3167–3176PubMedCrossRef
129.
Liu B, Yan S, Jia Y et al (2016) TLR2 promotes human intrahepatic cholangiocarcinoma cell migration and invasion by modulating NF-kappaB pathway-mediated inflammatory responses. FEBS J 283:3839–3850PubMedCrossRef
130.
Li K, Dan Z, Hu X et al (2013) CD14 regulates gastric cancer cell epithelialmesenchymal transition and invasion in vitro. Oncol Rep 30:2725–2732PubMedCrossRef
131.
Liu YD, Ji CB, Li SB et al (2018) Toll-like receptor 2 stimulation promotes colorectal cancer cell growth via PI3K/Akt and NF-kappaB signaling pathways. Int Immunopharmacol 59:375–383PubMedCrossRef
132.
Li D, Gu R, Yang X et al (2014) TLR3 correlated with cervical lymph node metastasis in patients with papillary thyroid cancer. Int J Clin Exp Med 7:5111–5117PubMedPubMedCentral
133.
Chuang HC, Huang CC, Chien CY, Chuang JH (2012) Toll-like receptor 3-mediated tumor invasion in head and neck cancer. Oral Oncol 48:226–232PubMedCrossRef
134.
Zhang Y, Wang Q, Ma A et al (2014) Functional expression of TLR9 in esophageal cancer. Oncol Rep 31:2298–2304PubMedCrossRef
135.
O'Leary DP, Bhatt L, Woolley JF et al (2012) TLR-4 signalling accelerates colon cancer cell adhesion via NF-kappaB mediated transcriptional up-regulation of Nox-1. PLoS ONE 7:e44176PubMedPubMedCentralCrossRef
136.
Rousseau MC, Hsu RY, Spicer JD et al (2013) Lipopolysaccharide-induced toll-like receptor 4 signaling enhances the migratory ability of human esophageal cancer cells in a selectin-dependent manner. Surgery 154:69–77PubMedCrossRef
137.
Molteni M, Marabella D, Orlandi C, Rossetti C (2006) Melanoma cell lines are responsive in vitro to lipopolysaccharide and express TLR-4. Cancer Lett 235:75–83PubMedCrossRef
138.
Xie W, Huang Y, Xie W et al (2010) Bacteria peptidoglycan promoted breast cancer cell invasiveness and adhesiveness by targeting toll-like receptor 2 in the cancer cells. PLoS ONE 5:e10850PubMedPubMedCentralCrossRef
139.
Bondhopadhyay B, Moirangthem A, Basu A (2015) Innate adjuvant receptor Toll-like receptor 3 can promote breast cancer through cell surface. Tumour Biol 36:1261–1271PubMedCrossRef
140.
Hansen MT, Forst B, Cremers N et al (2015) A link between inflammation and metastasis: serum amyloid A1 and A3 induce metastasis, and are targets of metastasis-inducing S100A4. Oncogene 34:424–435PubMedCrossRef
141.
142.
143.
El Rayes T, Catena R, Lee S et al (2015) Lung inflammation promotes metastasis through neutrophil protease-mediated degradation of Tsp-1. Proc Natl Acad Sci USA 112:16000–16005PubMedCrossRefPubMedCentral
144.
145.
Yan L, Cai Q, Xu Y (2013) The ubiquitin-CXCR4 axis plays an important role in acute lung infection-enhanced lung tumor metastasis. Clin Cancer Res 19:4706–4716PubMedPubMedCentralCrossRef
146.
147.
Brown KA, Brain SD, Pearson JD et al (2006) Neutrophils in development of multiple organ failure in sepsis. Lancet 368:157–169PubMedCrossRef
148.
Lieto E, Galizia G, Auricchio A et al (2017) Preoperative neutrophil to lymphocyte ratio and lymphocyte to monocyte ratio are prognostic factors in gastric cancers undergoing surgery. J Gastrointest Surg 21:1–11CrossRef
149.
150.
McDonald B, Urrutia R, Yipp BG et al (2012) Intravascular neutrophil extracellular traps capture bacteria from the bloodstream during sepsis. Cell Host Microbe 12:324–333PubMedCrossRef
151.
Najmeh S, Cools-Lartigue J, Rayes RF et al (2017) Neutrophil extracellular traps sequester circulating tumor cells via beta1-integrin mediated interactions. Int J Cancer 140:2321–2330PubMedCrossRef
152.
Tohme S, Yazdani HO, Al-Khafaji AB et al (2016) Neutrophil extracellular traps promote the development and progression of liver metastases after surgical stress. Cancer Res 76:1367–1380PubMedPubMedCentralCrossRef
153.
154.
Albrengues J, Shields MA, Ng D et al (2018) Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science 361:eaao4227PubMedPubMedCentralCrossRef
155.
156.
Huhta H, Helminen O, Lehenkari PP et al (2016) Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett's esophagus, dysplasia and adenocarcinoma. Oncotarget 7:23658–23667PubMedPubMedCentralCrossRef
157.
Lan F, Yue X, Ren G et al (2015) miR-15a/16 enhances radiation sensitivity of non-small cell lung cancer cells by targeting the TLR1/NF-kappaB signaling pathway. Int J Radiat Oncol Biol Phys 91:73–81PubMedCrossRef
158.
Ayari C, Bergeron A, LaRue H et al (2011) Toll-like receptors in normal and malignant human bladders. J Urol 185:1915–1921PubMedCrossRef
159.
Pimentel-Nunes P, Afonso L, Lopes P et al (2011) Increased expression of toll-like receptors (TLR) 2, 4 and 5 in gastric dysplasia. Pathol Oncol Res 17:677–683PubMedCrossRef
160.
Szczepanski M, Stelmachowska M, Stryczynski L et al (2007) Assessment of expression of toll-like receptors 2, 3 and 4 in laryngeal carcinoma. Eur Arch Otorhinolaryngol 264:525–530PubMedCrossRef
161.
Saint-Jean M, Knol AC, Nguyen JM et al (2011) TLR expression in human melanoma cells. Eur J Dermatol 21:899–905PubMedCrossRef
162.
Ng LK, Rich AM, Hussaini HM et al (2011) Toll-like receptor 2 is present in the microenvironment of oral squamous cell carcinoma. Br J Cancer 104:460–463PubMedCrossRef
163.
Zhou M, McFarland-Mancini MM, Funk HM et al (2009) Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunol Immunother 58:1375–1385PubMedCrossRef
164.
Gonzalez-Reyes S, Marin L, Gonzalez L et al (2010) Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer 10:665PubMedPubMedCentralCrossRef
165.
Sheyhidin I, Nabi G, Hasim A et al (2011) Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J Gastroenterol 17:3745–3751PubMedPubMedCentralCrossRef
166.
Eiro N, Ovies C, Fernandez-Garcia B et al (2013) Expression of TLR3, 4, 7 and 9 in cutaneous malignant melanoma: relationship with clinicopathological characteristics and prognosis. Arch Dermatol Res 305:59–67PubMedCrossRef
167.
Gonzalez-Reyes S, Fernandez JM, Gonzalez LO et al (2011) Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunother 60:217–226PubMedCrossRef
168.
Schmausser B, Andrulis M, Endrich S et al (2005) Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol 295:179–185PubMedCrossRef
169.
MacRedmond R, Greene C, Taggart CC et al (2005) Respiratory epithelial cells require Toll-like receptor 4 for induction of human beta-defensin 2 by lipopolysaccharide. Respir Res 6:116PubMedPubMedCentralCrossRef
170.
Huang B, Zhao J, Li H et al (2005) Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65:5009–5014PubMedCrossRef
171.
Zhang YB, He FL, Fang M et al (2009) Increased expression of Toll-like receptors 4 and 9 in human lung cancer. Mol Biol Rep 36:1475–1481PubMedCrossRef
172.
Song C, Chen LZ, Zhang RH et al (2006) Functional variant in the 3′-untranslated region of Toll-like receptor 4 is associated with nasopharyngeal carcinoma risk. Cancer Biol Ther 5:1285–1291PubMedCrossRef
173.
Fan P, Zhang JJ, Wang B et al (2012) Hypoxia-inducible factor-1 up-regulates the expression of Toll-like receptor 4 in pancreatic cancer cells under hypoxic conditions. Pancreatology 12:170–178PubMedCrossRef
174.
Cai Z, Sanchez A, Shi Z et al (2011) Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res 71:2466–2475PubMedPubMedCentralCrossRef
175.
Kim WY, Lee JW, Choi JJ et al (2008) Increased expression of Toll-like receptor 5 during progression of cervical neoplasia. Int J Gynecol Cancer 18:300–305PubMedCrossRef
176.
Rhee SH, Im E, Pothoulakis C (2008) Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology 135:518–528PubMedCrossRef
177.
Song EJ, Kang MJ, Kim YS et al (2011) Flagellin promotes the proliferation of gastric cancer cells via the Toll-like receptor 5. Int J Mol Med 28:115–119PubMed
178.
Chen SK, Chung CA, Cheng YC et al (2014) Toll-like receptor 6 and connective tissue growth factor are significantly upregulated in mitomycin-C-treated urothelial carcinoma cells under hydrostatic pressure stimulation. Genet Test Mol Biomark 18:410–416CrossRef
179.
Garau G, Rocca PC, Manca A et al (2015) Preliminary study on the expression of Toll-like receptors 7 and 8 in bladder urothelial tumors. Urologia 82:226–228PubMedCrossRef
180.
Grimm M, Kim M, Rosenwald A et al (2010) Toll-like receptor (TLR) 7 and TLR8 expression on CD133+ cells in colorectal cancer points to a specific role for inflammation-induced TLRs in tumourigenesis and tumour progression. Eur J Cancer 46:2849–2857PubMedCrossRef
181.
Wang F, Jin R, Zou BB et al (2016) Activation of Toll-like receptor 7 regulates the expression of IFN-lambda1, p53, PTEN, VEGF, TIMP-1 and MMP-9 in pancreatic cancer cells. Mol Med Rep 13:1807–1812PubMedCrossRef
182.
Zhang Y, Yang H, Barnie PA et al (2014) The expression of Toll-like receptor 8 and its relationship with VEGF and Bcl-2 in cervical cancer. Int J Med Sci 11:608–613PubMedPubMedCentralCrossRef
183.
Berger R, Fiegl H, Goebel G et al (2010) Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci 101:1059–1066PubMedCrossRef
184.
Lee JW, Choi JJ, Seo ES et al (2007) Increased toll-like receptor 9 expression in cervical neoplasia. Mol Carcinog 46:941–947PubMedCrossRef
185.
Ronkainen H, Hirvikoski P, Kauppila S et al (2011) Absent Toll-like receptor-9 expression predicts poor prognosis in renal cell carcinoma. J Exp Clin Cancer Res 30:84PubMedPubMedCentralCrossRef
Metadata
Title
Toll-like receptors: exploring their potential connection with post-operative infectious complications and cancer recurrence
Authors
S. D. Gowing
J. J. Cool-Lartigue
J. D. Spicer
A. J. E. Seely
L. E. Ferri
Publication date
01-04-2020
Publisher
Springer Netherlands
Keyword
Metastasis
Published in
Clinical & Experimental Metastasis / Issue 2/2020
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-020-10018-2

Other articles of this Issue 2/2020

Clinical & Experimental Metastasis 2/2020 Go to the issue

Research Paper

Exploratory cost-effectiveness analysis of 68Gallium-PSMA PET/MRI-based imaging in patients with biochemical recurrence of prostate cancer

Research Paper

Breast brain metastases are associated with increased risk of leptomeningeal disease after stereotactic radiosurgery: a systematic review and meta-analysis

Research Paper

Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition

Research Paper

Hepatic artery infusion pump for nasopharyngeal carcinoma with liver metastasis

Research Paper

Skeletal impact of 17β-estradiol in T cell-deficient mice: age-dependent bone effects and osteosarcoma formation

Research Paper

Impact of decompressive laminectomy on the functional outcome of patients with metastatic spinal cord compression and neurological impairment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits